Lazcluze (Lazertinib Mesilate Monohydrate)

• Lazcluze is a targeted therapy that acts on EGFR‑mutated non‑small cell lung cancer.
• Non‑small cell lung cancer with EGFR mutations: improves progression‑free survival and tumor response in patients whose tumours harbor activating EGFR alterations.

• Lazertinib mesilate monohydrate selectively inhibits the tyrosine kinase activity of the epidermal growth factor receptor (EGFR), including common activating mutations such as exon 19 deletions and L858R. By blocking ATP binding to the mutant EGFR kinase domain, it prevents downstream signaling pathways that drive cell proliferation and survival, leading to tumor growth inhibition.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Diarrhea: mild to moderate gastrointestinal upset.
• Skin rash: papulopustular eruption, often on the face or trunk.
• Nausea: occasional feeling of queasiness.
• Decreased appetite: reduced food intake.
• Fatigue: general tiredness.
• Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects

• Interstitial lung disease: new or worsening respiratory symptoms.
• Severe hepatic injury: marked elevation of liver enzymes or jaundice.
• QT interval prolongation: potential cardiac arrhythmia risk.
• Stevens‑Johnson syndrome: severe skin and mucosal reactions.
• Grade 3/4 neutropenia: significant reduction in white blood cells.
• Hepatotoxicity: liver failure requiring medical intervention.

• Patients should be monitored for specific safety concerns before and during treatment.
• Liver function monitoring: assess ALT, AST, and bilirubin regularly.
• Cardiac assessment: obtain baseline ECG and monitor QT interval.
• Pulmonary evaluation: watch for signs of interstitial lung disease.
• Avoid use in severe hepatic impairment: contraindicated in patients with Child‑Pugh C.
• Drug interaction awareness: review concomitant medications that affect CYP3A4.
• Store at below 25°C: keep in original container, protect from moisture and light.

Lazcluze may interact with other medicines that influence its metabolism or cardiac safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.
• QT‑prolonging agents (e.g., certain antiarrhythmics): additive risk of arrhythmia.

Moderate Interactions (Monitor Closely):\n- Antacids containing aluminum or magnesium: may affect absorption, separate dosing by at least 2 hours.

• Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise drug levels.
• Warfarin: monitor INR as EGFR inhibitors can alter coagulation parameters.